| dc.description | THEORETICAL FOUNDATIONS AND USE OF MULTI-CRITERIA DECISION ANALYSIS IN THE PHARMACEUTICAL SECTOR OF UKRAINE ACCORDING TO THE EUROPEAN REFORMING VECTORO.B. Piniazhko, O.M. ZaliskaDanylo Halytsky Lviv National Medical University The reforming of health care system has been started to carry out in Ukraine. Assessing the value of medical technologies may require new approaches that take into account a more comprehensive set of parameters than the incremental cost-effectiveness ratio, ICER/ quality adjusted life years, QALY.Technological advancements in combination with higher life expectancy, higher patient expectations, and increased prevalence of chronic diseases, have led to significant increases in public spending on pharmaceuticals, which, on average account for 9,3% of total health expenditure or about 1,4% of GDP across OECD countries (OECD, 2012). Given the resources governments and health systems can spend on healthcare, the pathway to optimal resource allocation passes through cost containment and efficiency improvement policies. In the context of multi-criteria decision analysis (MCDA), elements of value can be measured and scored in their natural units or through constructed scales, quantitatively or qualitatively, and weights are assigned to reflect criteria’s importance when combining them. This approach may provide a more comprehensive account of value parameters, greater transparency in how multiple criteria are explicitly valued, weighted, and aggregated, and a more inclusive approach to stakeholder views on value.Our aim was to perform a comparative analysis of the main approaches, methods and stages of MCDA, to determine the urgent and relevant use of MCDA in health care system of Ukraine based on the experience of developed countries.We have analyzed the ukrainian and foreign publications, articles, systematic reviews, practical guidelines on MCDA in health care using PubMed, EMBASE, Internet resources as search tools.Decision analysis can provide an alternative way of measuring and eliciting value. In particular, MCDA is both an approach and a set of techniques, with the goal of providing an overall ordering of options by looking at the extent to which a set of objectives are achieved. MCDA methodologies have been suggested for use in public services since 1960. MCDA has been used, on an experimental basis, in order to assess the benefit-risk (clinical) profile of new medicines for the purpose of regulatory approval during marketing authorisation stage by the European Medicines Agency and others. Its use has also been suggested in health care and value assessment in HTA also offering a conceptual framework.Although a variety of MCDA methodologies exist, the process of MCDA includes a number of common stages as follows: 1) establishing the decision context by defining the aims of the MDCA, and who the decision makers and other key stakeholders are; 2) identifying the objectives and criteria that reflect the value associated with the consequences of each option; 3) «scoring» the value associated with the performance of each option against the criteria; 4) «weighting» each of the criteria to reflect their relative importance to the decision; 5) examine the results; 6) conducting a sensitivity analysis of the results to test the influence of changes in scores or weights.As the results of our review we suggested the urgent and relevant use of MCDA in health care system of Ukraine based on the experience of developed countries. The comparative analysis of the main approaches, methods and stages of MCDA was performed and trends of it’s implementation in the pharmaceutical industry of our country were suggested.Due to the performed analysis, in our opinion in order to optimize and improve the decision-making process in health care the implementation of MCDA approach will provide transparent and consistent management decisions in Ukraine. | uk-UA |
